Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio

Global Eczema Therapeutics Market 2024-2028

News provided by

Technavio

Apr 08, 2024, 13:44 ET

Share this article

Share toX

Share this article

Share toX

NEW YORK, April 8, 2024 /PRNewswire/ -- The global eczema therapeutics market  size is estimated to grow by USD 5.81 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 10.28%  during the forecast period.  The global eczema therapeutics market holds potential due to the high prevalence of atopic dermatitis, affecting approximately 18 million people in the US, including 3 million children with moderate-to-severe forms. Causes include allergens, irritants, stress, infections, and genetics. Treatments encompass topical steroids, PDE4 inhibitors, antihistamines, immunomodulators, and emollients. Online pharmacies and hospitals provide access to steroid medicines, foam delivery systems, and other therapies. Key keywords include: eczema, atopic dermatitis, rashes, itchy skin, inflammation, skin irritation, hand dermatitis, corticosteroids, immunosystem, genes, probiotics, and Roseomonas mucosa. 

Continue Reading
Technavio has announced its latest market research report titled Global Eczema Therapeutics Market 2024-2028
Technavio has announced its latest market research report titled Global Eczema Therapeutics Market 2024-2028

For more insights on the historic (2018 - 2022) and forecast market size- Request a sample report

Eczema Therapeutics Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 - 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 10.28%

Market growth 2024-2028

USD 5.81 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

9.55

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key countries

US, Canada, Germany, UK, and China

Key companies profiled

AbbVie Inc., Alliance Pharma PLC, Amneal Pharmaceuticals Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd., Eli Lilly and Co., Incyte Corp., LEO Pharma AS, Lupin Ltd., Mayo Clinic, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Segment Overview 

This eczema therapeutics market report extensively covers market segmentation by Application (Atopic dermatitis, Contact dermatitis, Other indication) Distribution Channel (Hospital and clinics, Online pharmacies, Retail pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW))

Market segmentation by Application

The Atopic Eczema market caters to the treatment of this chronic skin disorder through various medical therapies. Hospitals and clinics, with their dermatology departments, diagnose and provide comprehensive care, including ointments, topical steroids, and injectable medicines for inflammation, itching, and skin redness. The drug class includes corticosteroids, PDE4 inhibitors, antihistamines, immunomodulators, and interleukin inhibitors. Emollients, available in online pharmacies, help maintain the skin barrier. Genetics play a role, with probiotics like Roseomonas mucosa offering potential solutions. Steroid medicines come in foam delivery systems, while hand sanitizers alleviate skin irritation in conditions like hand dermatitis. Treatment strategies also involve moisturizers, antibiotics, and antihistamines for symptom relief.

Geography Overview

The Atopic Eczema market in North America is a significant segment of the Skin Diseases industry, with a high prevalence of Atopic Dermatitis, a chronic and relapsing inflammatory skin disorder. Treatment options include topical therapies like ointments, steroids, and emollients, as well as injectable medicines such as corticosteroids and PDE4 inhibitors. Symptoms of eczema include itching, rashes, redness, and irritation. Drug classes like Antihistamines, Immunomodulators, and Interleukin inhibitors are also used. Online pharmacies and hospitals/clinics provide access to these medicines. Genetics and the immune system play a role in the disease, with research focusing on genes like those related to Roseomonas mucosa. Foam delivery systems and steroid creams are popular for application, while moisturizers, antibiotics, hand sanitizer, and probiotics offer additional relief. 

Insights on the market contribution of various segments including country and region wise, historic (2018 - 2022) and forecast market size- Download a Sample Report

  • The eczema therapeutics market encompasses various treatments for atopic eczema, including topical ointments with steroids and PDE4 inhibitors, injectable corticosteroids, antihistamines, immunomodulators, interleukin inhibitors, emollients, and antibiotics. Telemedicine platforms facilitate remote consultations, enabling dermatologists to prescribe these medications and offer educational resources. Keywords: Atopic eczema, treatments, topical steroids, PDE4 inhibitors, injectables, corticosteroids, antihistamines, immunomodulators, interleukin inhibitors, emollients, telemedicine.
  • The eczema therapeutics market faces lengthy regulatory approval processes, particularly for atopic dermatitis treatments. Novel drugs, including topical steroids, PDE4 inhibitors, antihistamines, and immunomodulators, are frequently evaluated in clinical trials. However, failure to meet trial endpoints can hinder approval, delaying product launches and market growth. Other treatments like corticosteroids, emollients, probiotics, and antibiotics are also used, often through online pharmacies or hospitals. Skin irritation, itching, redness, and rashes characterize eczema, requiring various medical therapies.

Insights on Market Drivers, trends, & Challenges, historic period(2018 - 2022) and forecast period(2024-2028)- Request a sample report!

Research Analysis

The Eczema Therapeutics Market encompasses a range of treatments for various skin disorders, including Atopic Dermatitis, Eczema, and Dermatitis. These conditions are characterized by symptoms such as rashes, skin redness, and itchy skin. The causes of these conditions are multifactorial, with genetics and immune system dysfunction playing significant roles. The skin barrier is often compromised, leading to inflammation and skin itching. Steroid creams and ointments, as well as topical steroids, are commonly used treatments for eczema and dermatitis. These medications help reduce inflammation and alleviate itching. Antihistamines may also be prescribed to help manage symptoms. However, long-term use of these treatments can have side effects, making the development of alternative, effective treatments a priority in the Eczema Therapeutics Market.

Market Research Overview

The Eczema Therapeutics Market encompasses a range of derivatics and topical solutions designed to address the symptoms and causes of eczema. These include, but are not limited to, Atopic Dermatitis Treatments, such as Eczemas, Cremas, and Ointments. Rashes and Skin Irritations are common issues for eczema patients, necessitating the use of Skin Care Products and Moisturizers. Itchy skin is a significant concern, with Genetics and Immune System responses playing a role. Topical Corticosteroids and Calcineurin Inhibitors are commonly used to treat eczema, while Systemic Therapies like PDE4 inhibitors and Biologics are used for severe cases. Treatment methods also include Antihistamines and Wet Wrap Therapy. The market for Eczema Therapeutics is expanding, with an increasing focus on developing innovative and effective solutions for those affected by this condition.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

  • Application
    • Atopic Dermatitis
    • Contact Dermatitis
    • Other Indication
  • Distribution Channel
    • Hospital And Clinics
    • Online Pharmacies
    • Retail Pharmacies
  • Geography
    • North America
    • Europe
    • Asia
    • Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.